| T vs. C | placebo plus SoC | carboplatin plus nab-paclitaxel | ipilimumab plus SoC | pembrolizumab plus SoC | atezolizumab plus carboplatin plus nab-paclitaxel | atezolizumab plus carboplatin plus paclitaxel |
| placebo plus SoC | --- | NA | NA | NA | NA | NA |
| carboplatin plus nab-paclitaxel | NA | --- | NA | NA | NA | NA |
| ipilimumab plus SoC | NA | NA | --- | NA | NA | NA |
| pembrolizumab plus SoC | NA | NA | NA | --- | NA | NA |
| atezolizumab plus carboplatin plus nab-paclitaxel | NA | NA | NA | NA | --- | NA |
| atezolizumab plus carboplatin plus paclitaxel | NA | NA | NA | NA | NA | --- |
pathologies: 308,164,166,220
- treatments: 744
result logic
